Key result
Isoproterenol during RFCA for paroxysmal AF fails to improve arrhythmia freedom but increases procedure time.
Why the study?
The effectiveness of isoproterenol for unmasking dormant conduction and non-PV triggers during AF RFCA and its impact on procedural and clinical outcomes remains controversial.
Does isoproterenol administration improve freedom from all-atrial arrhythmia in patients undergoing radiofrequency catheter ablation for paroxysmal atrial fibrillation?
Cohort (n=1,102)
Yes
Does isoproterenol administration improve freedom from all-atrial arrhythmia in patients undergoing radiofrequency catheter ablation for paroxysmal atrial fibrillation?
The use of isoproterenol to unmask dormant conduction during ablation for paroxysmal atrial fibrillation increases procedural time without improving 12-month freedom from atrial arrhythmias.
Answers are grounded in this paper and cite their sources.
May not justify routine isoproterenol use in paroxysmal AF ablation given longer procedures without arrhythmia benefit; leaves open need for randomized trials.
BACKGROUND: Pulmonary vein (PV) reconnection and the onset of non-PV triggers are frequently the cause of atrial fibrillation (AF) recurrence after radiofrequency catheter ablation (RFCA). The effectiveness of using isoproterenol for unmasking dormant conduction and non-PV-triggers during AF RFCA and its effect on improving procedural and clinical outcomes is still controversial. OBJECTIVE: To evaluate the effectiveness of isoproterenol for unmasking dormant conduction and non-PV triggers during RFCA for paroxysmal AF (PAF) and its effects on procedural and long-term clinical outcomes. METHODS: In this prospective multicenter cohort from the REAL-AF registry, patients who underwent RFCA for PAF with and without isoproterenol administration from January 2018 to May 2023 were included. The primary efficacy outcome was freedom from all-atrial arrhythmia at 12-month follow-up. Secondary outcomes included procedural and long-term clinical outcomes, and procedure-related complications. RESULTS: A total of 1102 patients were included (isoproterenol = 325 vs. control = 777) (mean age 66.73 ± 10.19 years; 53.05% male). There were no differences in baseline characteristics between the groups. Dormant conduction/non-PV triggers with isoproterenol were observed in 10.2% of the patients. Isoproterenol administration was associated with increased procedural times (109 (83-137.5) vs. 96 (74-122), p = 0.002), and decreased rates of first-pass PV isolation (74.84% vs. 80.14%, p = 0.007). There were no differences in freedom from all-atrial arrhythmias (HR 0.87, 95% CI [0.61-1.24], p = 0.4) or long-term clinical outcomes at 12 months of follow-up between the groups. CONCLUSION: In patients undergoing RFCA for PAF, the use of isoproterenol was associated with increased procedural times and more extensive ablation, without improved clinical outcomes at 12-month follow-up.
No takes yet. Share an insight, caveat, or question.
Oza et al. (2025) conducted a cohort in Paroxysmal atrial fibrillation (PAF) (n=1,102). Isoproterenol vs. Control (no isoproterenol) was evaluated on Freedom from all-atrial arrhythmia at 12-month follow-up (HR 0.87, 95% CI 0.61-1.24, p=0.4). Isoproterenol administration during RFCA for paroxysmal AF did not improve freedom from all-atrial arrhythmias at 12 months but increased procedural times.
Synapse has enriched 10 related papers. Consider them for comparative context: